Previous 10 | Next 10 |
2023-12-19 17:11:10 ET DENVER, Colo., Dec. 19, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Compugen Ltd (NASDAQ: CGEN), Gilead Sciences, Inc. (NASDAQ: GILD), Infobird Co Ltd (NASDAQ: IFBD), and Panbela Therapeutics Inc (NASDAQ: PBLA). Comp...
2023-12-19 10:56:18 ET More on Compugen, Gilead Sciences, etc. Gilead Sciences Is Building A Diversified Portfolio Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Presents at 6th Annua...
2023-12-19 10:25:45 ET An Illinois-based %Biotech company is already off to the races on Tuesday after it was announced that the company has entered into an agreement with %GileadSciences (Nasdaq: GILD) to exclusively license its potential first-in-class, pre-clinical antibody progr...
NORTHAMPTON, MA / ACCESSWIRE / December 19, 2023 / We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh, the first country globally to eliminate this life-thr...
2023-12-19 07:26:41 ET DENVER, Colo., Dec 19, 2023 ( www.247marketnews.com )- Gilead Sciences, Inc. (NASDAQ: GILD) and Compugen Ltd. (NASDAQ: CGEN) jointly announced, this morning, that they signed an exclusive license agreement for its potential first-in-class, pre-clinical antibody pr...
– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types – – Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment w...
2023-12-18 11:11:08 ET Summary The Health Care Select Sector SPDR Fund is a popular ETF that provides exposure to the healthcare sector. XLV has shown consistent performance and has outperformed the SPY ETF over the past decade. The ETF comprises major healthcare industry play...
2023-12-15 02:25:57 ET Summary Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. The company's most advanced molecule, domvanalimab, is being investigated in lung cancer and...
2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...
2023-12-12 13:00:16 ET Summary Gilead Sciences, Inc. had strong quarterly results, with total product sales of $6.3 billion and strong growth in HIV and Oncology. The company has several milestones, including the success of Trodelvy with over $1 billion in annualized sales. Gi...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...